tiprankstipranks

enGene Holdings Reports Q2 2025 Financial Results

enGene Holdings Reports Q2 2025 Financial Results

Engene Holdings Inc. ( (ENGN) ) has released its Q2 earnings. Here is a breakdown of the information Engene Holdings Inc. presented to its investors.

Don’t Miss TipRanks’ Half-Year Sale

enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing genetic medicines, particularly for treating Non-Muscle Invasive Bladder Cancer (NMIBC) using its proprietary Dually Derivatized Oligochitosan (DDX) platform. The company recently reported its second-quarter financial results for 2025, highlighting significant progress in its LEGEND study and strategic corporate developments. Key highlights from the report include strong enrollment in the pivotal cohort of the LEGEND study, which is crucial for the planned Biologics License Application (BLA) filing in mid-2026. Additionally, enGene completed the European Medicines Agency (EMA) Scientific Advice process, indicating potential for a Conditional Marketing Authorization Application. Financially, enGene reported a net loss of $25.8 million for the quarter, primarily due to increased research and development expenses related to the LEGEND study. Despite the losses, the company maintains a strong cash position of $251.5 million, expected to support operations into 2027. Looking ahead, enGene remains focused on advancing its clinical programs and achieving regulatory milestones, with the management optimistic about the potential impact of detalimogene on the treatment landscape for NMIBC.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1